Jacobi Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Jacobi Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$7K	–	1408
2020 Q3	$7K	Hold	200	–	–	﹤0.01%	895
2020 Q2	$3K	Hold	200	–	–	﹤0.01%	1027
2020 Q1	$3K	Hold	200	–	–	﹤0.01%	932
2019 Q4	$7K	Hold	200	–	–	﹤0.01%	818
2019 Q3	$4K	Buy	+200	New	+$4.08K	﹤0.01%	886

Jacobi Capital Management's AIMT Position: Q4 2020 in Review

Jacobi Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 200 shares — an estimated $7K sold.

Jacobi Capital Management first reported a position in AIMT in Q3 2019 and held it in 5 quarters. The position peaked at $7K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Jacobi Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Jacobi Capital Management sold 200 Aimmune Therapeutics shares in Q4 2020, an estimated $7K.
Jacobi Capital Management first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 5 quarters.
Jacobi Capital Management's Aimmune Therapeutics position peaked at $7K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Jacobi Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.